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Abstract
Virions are thought to contain all the essential proteins that govern virus egress from the host cell and initiation of
replication in the target cell. It has been known for some time that influenza virions contain nine viral proteins; however,
analyses of other enveloped viruses have revealed that proteins from the host cell can also be detected in virions. To
address whether the same is true for influenza virus, we used two complementary mass spectrometry approaches to
perform a comprehensive proteomic analysis of purified influenza virus particles. In addition to the aforementioned nine
virus-encoded proteins, we detected the presence of 36 host-encoded proteins. These include both cytoplasmic and
membrane-bound proteins that can be grouped into several functional categories, such as cytoskeletal proteins, annexins,
glycolytic enzymes, and tetraspanins. Interestingly, a significant number of these have also been reported to be present in
virions of other virus families. Protease treatment of virions combined with immunoblot analysis was used to verify the
presence of the cellular protein and also to determine whether it is located in the core of the influenza virus particle.
Immunogold labeling confirmed the presence of membrane-bound host proteins on the influenza virus envelope. The
identification of cellular constituents of influenza virions has important implications for understanding the interactions of
influenza virus with its host and brings us a step closer to defining the cellular requirements for influenza virus replication.
While not all of the host proteins are necessarily incorporated specifically, those that are and are found to have an essential
role represent novel targets for antiviral drugs and for attenuation of viruses for vaccine purposes.
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Introduction
Knowledge of the protein composition of a virus particle often
serves as an initial guide in determining functional roles for viral
proteins. Virion proteins are commonly termed ‘‘structural
proteins’’ and broadly-speaking, include proteins that either form
an integral part of the virus architecture or are required for the
first round of genome replication. This view of a virion being a
minimal package of genome and essential viral proteins is now
being challenged due to enhanced proteomics techniques and the
availability of annotated genomic sequences for several mamma-
lian species. These advances have extended proteomic analyses of
virions to include host proteins that may be packaged into the virus
particle along with the viral components. Enveloped viruses in
particular have the capability of incorporating numerous host
proteins, both into the interior of the virus particle as well as into
the lipid envelope [1,2]. Several proteomic studies on herpesvi-
ruses have been undertaken, the majority of which focused on
correctly identifying the viral constituents of the virion but many
also reported finding cellular proteins [3–9]. Similarly, host
proteins have been detected in vaccinia virions [10]. For RNA
viruses, extensive proteomic analysis has been performed on
human immunodeficiency virus type 1 (HIV-1) and Moloney
murine leukemia virus (MoMLV) vector particles, and they too
have been found to incorporate numerous cellular proteins [11–
13].
For the most part the functional significance of these packaged
host proteins has not yet been determined but some proteins are
known to interact specifically with a viral protein and this has
enabled the significance of their incorporation to be studied in more
depth. These include Tsg101, cyclophilin A and APOBEC3G, all of
which are packaged into HIV-1 virions [11,12,14–17]. Tsg101 plays
a crucial role in virus assembly [14,18], cyclophilin A modulates
HIV-1 infectivity [19] and APOBEC3G is an anti-viral factor that
promotes hypermutation of the viral genome [20]. These three
proteins alone have significantly added to the understanding of how
HIV-1 interacts with its host and they serve as an example of what
can be learned from studying virion-associated host proteins.
Although there are descriptions of interactions between certain
cellular proteins and individual influenza virus proteins, for the most
part this has not been done in a comprehensive manner and
comparatively little is known about the requirement for host cell
factors during the different stages of the influenza virus life cycle. In
an effort to discover host factors involved particularly in genome
replication, proteomic analyses of native influenza virus ribonucleo-
protein and polymerase complexes have been performed which
resultedintheidentificationof45interactingcellularproteins[21].It
is anticipated that cellular proteins found within the influenza virus
particle may provide clues as to the virus assembly pathway and also
early events that govern virus infectivity.
Of the eleven influenza A virus encoded proteins, nine have
been identified in the virion [22]. The exceptions being NS1 and
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viruses. The glycoproteins hemagglutinin (HA) and neuraminidase
(NA) are embedded into the lipid envelope of the virus particle and
form the characteristic spikes visible under the electron microscope
[23–25]. Another membrane protein, the ion channel protein M2
is also found within the virion but at significantly lower levels than
HA or NA [26]. The matrix protein M1 lies beneath the viral
membrane and surrounds the eight ribonucleoprotein (RNP)
segments, which consist of viral RNA coated with the nucleopro-
tein (NP) and bound by the trimeric polymerase complex (PB1,
PB2, PA) [25,27]. Finally the nuclear export protein (NEP) is also
found within influenza virions [28]. The majority of these proteins
were identified on the basis of size by polyacrylamide gel
electrophoresis but because detection of proteins by this method
is restricted to more highly abundant proteins, the presence of M2
and NEP proteins in the influenza virion was only discovered
much later using specific antibodies [26,28]. Any cellular proteins
that may be incorporated into viral particles are also likely to be
present at very low levels and while antibody-mediated detection is
extremely sensitive, it is not practical when analyzing complexes of
unknown composition. Mass spectrometry of tryptic peptides
combined with database searching for identification is now the
preferred method for such proteomic studies. In this report we
utilize two complementary mass spectrometry techniques to
analyze the protein content of purified influenza virus particles
and specifically, to identify incorporated cellular proteins. Our
analysis resulted in the identification of 9 virus-encoded proteins
and 36 host-encoded proteins.
Results
Purification of influenza virus
Virion proteomic analysis requires a highly purified preparation
of virus and the choice of host cell used for virus growth is also an
important consideration. While MDCK (Madin Darby canine
kidney) cells are the preferred cell line for growth of influenza virus
in tissue culture, the dog genome is not yet fully annotated and this
would restrict the identification of cellular proteins. For the same
reason, virus grown in embryonated chicken eggs was also not the
best option. As a compromise between cells that would support
high levels of virus growth and cells that could be used to search
the most extensive protein database (i.e. human), Vero (African
green monkey kidney) cells were selected as the host cell line.
There are a growing number of non-human primate sequences in
the NCBI database and because of significant homology between
primate and human proteins the human protein database could be
used to identify incorporated host proteins. For later comparison,
smaller amounts of virus were also purified from infected A549
(human carcinoma lung epithelial) cells. Supernatant collected
from Vero cells infected with influenza A/WSN/33 virus was first
clarified and the virus was concentrated through a sucrose cushion
before being purified over a 30–60% sucrose gradient. The purity
of the virus preparation was assessed by electron microscopy
following negative staining (Fig. 1A). Both intact influenza virions
and partially disrupted virions were observed but importantly,
there was no obvious contamination with cellular material. The
proteins in the purified virus preparation were separated by SDS-
PAGE and stained with Coomassie blue, and for identification of
the viral glycoproteins, a deglycosylated sample was compared to
an untreated sample (Fig. 1B). All major viral proteins were visible.
The three polymerase proteins resolved as two bands, both
uncleaved (HA0) and cleaved (HA1 and HA2) forms of HA were
present, as were bands consistent with the molecular weights for
NP, NA and M1. There were also some much fainter bands visible
that may represent cellular proteins.
Proteomic analysis of influenza virions
The ability to fractionate protein samples to enhance the dynamic
range of detectable proteins is a key issue when identifying the
components of a protein complex by mass spectrometry. For this
study two complementary techniques were used, one of which is
based on separation of proteins and the other on separation of
peptides. For the first method, both glycosylated and deglycosylated
virus preparations were separated by SDS-PAGE on an 8–16%
gradient gel (Fig. 1B). Deglycosylation is required for several reasons:
Firstly, because trypsin does not always efficiently digest highly
glycosylated proteins and, secondly, because unmodified peptides
generally have higher electrospray ionization efficiencies than their
glycosylated counterparts. Finally, because deglycosylation produces
a more uniform set of peptides from a potentially diverse number of
glycoprotein isoforms, the sensitivity is increased. That said, in this
study we did not find that deglycosylation increased the number of
proteins identified (see Tables S1 and S2 for a comparison) and
therefore the reported identifications from the two approaches were
combined. Following Coomassie blue staining, each lane was cut
into successive slices from top to bottom and the individual slices
were subjected to in-gel trypsin digestion. This procedure was
repeated on a 20% gel and gel slices less than 25 kDa were excised,
so as to maximize the chances of detecting small molecular weight
proteins. The peptides in each gel slice were then analyzed by liquid
chromatography tandem mass spectrometry (LC-MS/MS) and the
resulting fragment ion spectra were searched against protein
databases for identification.
The second method employed in this study was multidimensional
protein identification technology (MudPIT). A deglycosylated
purified virus preparation was digested with trypsin en masse and
the peptides in the mixture were separated by two dimensional
chromatography, first on the basis of charge and then on
hydrophobicity. The second chromatography separation step was
directly coupled to the mass spectrometer detector and the resulting
spectra were searched against the database for protein identification.
The disadvantage of MudPIT is that there is no information on the
size of the proteins which is useful for confirmation of protein
identity. However, the method allows for the detection of low
Author Summary
Viruses are released from infected cells in the form of
virions, which contain all the essential factors necessary for
initiating infection in a new target cell. For influenza virus,
it is known that virions contain the viral genome, a lipid
envelope, and at least nine viral proteins. We performed a
detailed proteomic analysis of purified influenza virus
particles using mass spectrometry and database searching
for protein identification, and in addition to the nine viral
proteins, we identified 36 host proteins. These host
proteins are present both inside the influenza virus particle
and on the viral envelope. All viruses require host cell
factors to complete their replication cycles, and they also
have to contend with the antiviral defense mechanisms of
the host. Virus–host interactions may therefore provide the
key to understanding viral pathogenesis and may also
present us with new targets for the design of antiviral
drugs. For influenza virus, information on the requirement
of cellular factors is limited, but the description of these 36
host proteins that are packaged into the virion provides a
foundation for further analysis into the involvement of
these cellular pathways in the influenza virus life cycle.
Host Proteins in Influenza Virions
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that are often lost during gel-separation or gel-extraction steps.
Identification of influenza virus-encoded virion proteins
All nine virus-encoded proteins previously described to be in the
influenza virion were identified by both MS methods (Table 1).
These are PB1, PB2, PA, HA, NP, NA, M1, M2 and NEP.
Peptides from NS1 or PB1-F2 were not detected. Table 1 lists the
predicted mass of each protein, the gel slice in which it was
detected, the number of observed peptides and the percent
sequence coverage of the protein. The statistical score associated
with the match is also noted. MASCOT scores are used for the
SDS-PAGE and LC-MS/MS analysis, while protein prophet
Figure 1. Analysis of purified influenza virus preparations. (A) Electron micrograph of negatively stained, sucrose gradient purified influenza
A/WSN/33 virus at 50,0006magnification. (B) SDS-PAGE separation of proteins in a purified influenza virus preparation. 15 ug of untreated (lane 1) or
deglycosylated (lane 2) proteins were separated on an 8–16% polyacrylamide gel and stained with Coomassie blue. The positions of the viral proteins,
identified by their predicted molecular weights, are indicated.
doi:10.1371/journal.ppat.1000085.g001
Table 1. Virion-associated influenza virus proteins identified by mass spectrometry.
SDS-PAGE and LC-MS/MS Analysis MudPIT Analysis
Protein
name Mass (Da) Gel slice
a
No. of
observed
peptides
c
Mascot
score
e
Sequence
coverage (%)
f
No. of
observed
peptides
c
Protein
prophet
score
e
Sequence
coverage (%)
f
PB1 86516 10 35 700 37.1 5 1 8.6
PB2 85796 11 34 768 35.6 17 1 23.7
PA 82531 11 23 458 28.2 5 1 9.4
HA 63525 11–17,21–24,26–34,
38–43,48
2–70
d 54–546
d 29.4 22 1 40.4
NP 56244 15–19,23,27,30 5–61
d 66–1073
d 46.8 32 1 35.3
NA 49689 20–21,28 3–6
d 52–98
d 15.5 9 1 22.7
M1 27864 32–46 3–102
d 76–787
d 66.3 12 0.98 34.7
M2 11313 46–47 2–3
d 39–101
d 48.5 1 0.96 11.3
NEP 14327 15
b 7 77 31.4 1 0.95 7.4
aGel slices were numbered consecutively from the top to the bottom of an 8–16% gel.
bFrom a higher percentage gel.
cObserved peptides include all peptides that differ either by sequence, modification or charge.
dValues represent the range when the protein was found in multiple gel slices.
eA Mascot score $50 and a Protein prophet score $0.95 are equivalent (p,0.05).
fSequence coverage is based on peptides with unique sequence.
doi:10.1371/journal.ppat.1000085.t001
Host Proteins in Influenza Virions
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M1 proteins were all found in multiple gel slices. For HA, this was
expected due to the presence of uncleaved HA0 as well as the
cleaved sub-units HA1 and HA2. However for both HA and
particularly NP and M1, the proteins appear to be distributed over
a wider-than-expected size range. This perhaps reflects the fact
that they are predicted to be the most abundant proteins in the
influenza virion [27] and these amounts may exceed the resolving
capacity of the gel, causing them to smear. From their predicted
size, PB1 and PB2 are expected to migrate together, however in
fact we found that PB1 migrates slower than PB2, which resolves
together with PA. This is in agreement with the first mapping data
for the assignment of protein products to RNA segments [29] but
the reason for the different migration patterns of PB1 and PB2 is
still not known. Generally, the sequence coverage for each protein,
which represents the number of unique peptides identified, was
greater with the gel-fractionation and LC-MS/MS analysis. The
exceptions are HA and NA, where greater sequence coverage was
obtained with the MudPIT analysis.
Identification of virion-associated cellular proteins
In total, we identified 36 cellular proteins in the purified
influenza virus preparation. Seventeen of these were identified by
both MS methods (Table 2), another 13 were identified only with
the MudPIT analysis (Table 3) and 6 were identified only with the
gel-fractionation and LC-MS/MS analysis (Table 4). Each table
indicates the protein name, its predicted mass, the gel slice in
which it was found (where relevant), the number of observed
peptides, the score associated with the match and the percent
sequence coverage. In addition, the predicted cellular localization
of the protein is shown along with its abundance at the transcript
level. Abundance in the kidney is noted because of the use of Vero
cells, while abundance in the lung is more biologically relevant for
influenza virus. The final column lists other viruses that have been
reported to incorporate the observed cellular protein into their
virions.
As with the viral proteins, comparison between the two MS
methods reveals greater sequence coverage obtained with the
gel-separated proteins, however in total more proteins were
identified with the MudPIT analysis. Both cytoplasmic and
membrane-bound proteins were identified and while several of
these proteins are highly abundant according to their NCBI
UniGene EST profiles, most do not fall into this category and
are present at moderate or low abundance in the cell. It is also
striking that the majority of the proteins, particularly those in
Table 2 have been reported in other virus particles and that
many proteins are related or can be grouped together in
functional categories such as cytoskeletal components, glycolytic
enzymes and annexins.
Confirmation of cellular protein incorporation into
influenza virions
Following identification of the cellular proteins by proteomic
methods, their presence in the purified influenza virus preparation
was verified by immunoblot analysis which provides the highest
degree of specificity. Influenza virus preparations purified from
both Vero and A549 cells were analyzed for the presence of HA,
beta-actin, annexin A5 and cyclophilin A (Fig. 2). Extracts from
uninfected Vero and A549 cells were included as a control for the
reactivity of the antibodies and size of the cellular protein.
Influenza virus purified from both cell lines showed the presence of
these three cellular proteins, confirming that they are associated
Table 3. Cellular proteins in purified influenza virions identified only by MudPIT LC-MS/MS analysis.
MudPIT Analysis
Protein Name
Entrez
Gene ID
No. of
observed
peptides
a
Protein
prophet
score
b
sequence
coverage
(%)
c Cellular localization
Expression
profile (TPM)
d
Reported in other
viruses
Kidney Lung
CD59 966 3 1 27.8 membrane 293 271 HCMV [81], HTLV-1 [81],
HIV-1 [80], VV [82]
29,39-cyclic nucleotide 39
phosphodiesterase
1267 1 1 11.7 cytoplasm/membrane? 369 65 HIV-1 [11]
ubiquitin carboxyl-terminal
hydrolase L1
7345 1 1 14.8 cytoplasm/membrane? 175 494
fatty acid synthase 2194 1 1 5.7 cytoplasm 33 238
gamma-glutamyltransferase 1 2678 2 1 4 membrane 4 23 HIV-1 [11]
HSP 27 kDa 3315 2 1 13.6 cytoplasm/nucleus 364 503 HIV-1 [90]
WD repeat-containing protein 1 9948 2 1 5.2 cytoplasm 639 288
phosphoglycerate kinase 5230 1 0.99 15.9 cytoplasm 833 479 HIV-1 [11], HCMV [3]
diazepam binding inhibitor 1622 1 0.99 23.8 cytoplasm/membrane? 113 80
transgelin 6876 1 0.98 6 cytoplasm 113 342
S100 calcium-binding protein A11 6282 1 0.97 10.9 cytoplasm/membrane 174 243 HIV-1 [11]
integrin beta 1 3688 1 0.97 12.5 membrane 198 186 HIV-1[11], MoMLV[13]
annexin A11 311 1 0.9 2.2 cytoplasm/membrane 175 232 HIV-1 [11]
aObserved peptides include all peptides that differ either by sequence, modification or charge.
bA Protein prophet score $0.95 is significant (p,0.05).
cSequence coverage is based on peptides with unique sequence.
dNCBI UniGene EST profile, TPM=Transcripts per million.
doi:10.1371/journal.ppat.1000085.t003
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two different cell types.
When analyzing the results of virion proteomic studies, the
challenge is to prove that the cellular proteins are really an
integral part of the virion and that they are not just attached
non-specifically to the outside or are perhaps derived from a
microvesicle or exosome that co-purified with the virus. To
address this question, we used the subtilisin protease protection
assay which has been shown to efficiently remove microvesicles
from HIV-1 virion preparations [30,31]. Protease treatment of
the purified virus preparation strips proteins off the outside of
virus particles and off any contaminating microvesicles. In doing
so, the microvesicles become lighter than the virions and
therefore the virions can be isolated by density centrifugation.
Proteins that are inside the virion are protected by the lipid
envelope and therefore will remain after the protease treatment.
This is illustrated by the presence and absence of NP and HA,
respectively, after subtilisin treatment of influenza virions (Fig. 3).
Immunoblot analysis of selected cellular proteins reveals that
beta-actin, annexin A5, tubulin, annexin A2, cofilin, GAPDH
and cyclophilin A are all still present following protease
treatment and centrifugation (Fig. 3). This indicates that these
proteins are inside the influenza virion, however it should be
noted that these experiments do not absolutely exclude the
possibility that some proteins may be derived from contaminants
that were not efficiently removed by the protease treatment. In
contrast, CD9 and CD59 are absent following treatment (Fig. 3).
There are two possible interpretations of this finding: Firstly,
their loss may be because they are associated with microvesicles
rather than virions and secondly, these proteins may be exposed
on the surface of the virion as is HA. Since CD9 and CD59 are
both membrane-bound proteins found on cellular surfaces (CD9
has two extracellular loops and CD59 is GPI-anchored), if they
are incorporated into an influenza virus particle one would
expect them to be in the viral envelope and thus sensitive to
protease digestion. However, to further address the possibility
that they are not part of the virion, we made use of an alternative
gradient medium (Optiprep) which, unlike sucrose, maintains
iso-osmotic conditions at high densities and is therefore
particularly good at separating membranous organelles such as
enveloped viruses and microvesicles. Influenza virus preparations
were purified simultaneously over both sucrose and Optiprep
gradients, which were then fractionated. Immunoblot analysis
demonstrated that CD9 co-sediments precisely with influenza
virus (as detected by the presence of NP) in both types of
Table 4. Cellular proteins identified in purified influenza virions only by gel fractionation LC-MS/MS analysis.
SDS-PAGE and LC-MS/MS Analysis
Protein Name
Entrez
Gene ID
Mass
(Da)
Gel
slice
a
No. of
observed
peptides
b
MASCOT
score
c
Sequence
coverage
(%)
d Cellular localization
Expression
profile (TPM)
e
Reported in other
viruses
kidney lung
aldo-keto reductase 231 35854 29 5 101 23.1 cytoplasm 653 214
annexin A5 308 35937 29* 5 226 15.6 cytoplasm/membrane 113 247 HCMV [3], HIV-1 [11]
tropomyosin 4 7171 28522 31 7 138 21.4 cytoplasm 108 83
peroxiredoxin 1 5052 22110 39 4 85 19.6 cytoplasm 326 545 VV [10], HIV-1 [11],
MoMLV [13]
destrin 11034 15397 45 4 113 32.6 cytoplasm 137 157
ubiquitin 7314 8565 18
# 23 9
1 32.9 cytoplasm/nucleus 169 183 HIV-1 [11,12,91], SIV [91],
MoMLV [13,91], VV [10]
*Best sequence coverage was obtained with the deglycosylated sample.
aGel slices were numbered consecutively from the top to the bottom of an 8–16% gel.
#From a higher percentage gel.
bObserved peptides include all peptides that differ either by sequence, modification or charge.
cA Mascot score $50 is significant (p,0.05).
dSequence coverage is based on peptides with unique sequence.
1For this search a Mascot score $38 is significant (p,0.05).
eNCBI UniGene EST profile, TPM=Transcripts per million.
doi:10.1371/journal.ppat.1000085.t004
Figure 2. Confirmation of host protein incorporation into
influenza virions derived from different cell lines. Influenza A/
WSN/33 virus was purified from the supernatant of infected A549 and
Vero cells. 2 ug of purified virus derived from A549 and Vero cells (lane
1 and 2, respectively) and 10 ug of cellular extracts from uninfected
A549 and Vero cells (lanes 3 and 4, respectively) were subjected to
western blot analysis with antibodies against the following proteins: (A)
Influenza hemagglutinin (HA0 and HA1 are visible), (B) Beta actin, (C)
Annexin A5, (D) Cyclophilin A. Numbers to the left are molecular weight
markers.
doi:10.1371/journal.ppat.1000085.g002
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which has been found in exosomes derived from a variety of cell
types [32–34] but was not identified in the mass spectrometry
analysis of purified influenza virus. In the sucrose gradient, the
peak MHC-I staining overlaps partially with that of NP and
CD9 but in the Optiprep gradient there is clear separation of
MHC-I from virus and CD9. This supports the idea that
Optiprep allows for better separation and strongly suggests that
CD9 is an integral part of the influenza virion. It should also be
noted that despite partial co-purification of MHC-I in the
sucrose gradient, this protein was not identified in the proteomic
analysis, probably indicating that the level of sensitivity provided
by these methods is not sufficient to detect very low levels of
protein.
To provide additional evidence that the membrane-bound
cellular proteins identified by mass spectrometry are on the lipid
envelope of influenza virus, immunogold labeling of Optiprep-
purified influenza virions was performed. Virions were labeled
with antibodies against HA, CD9, CD81 (Fig. 5) or CD59 (data
not shown) and secondary gold antibodies, followed by negative
staining. One or two gold particles located on the surface of a
virion could be seen for CD9, CD81 and CD59. This was
significantly less compared with the degree of HA labeling,
however it is consistent with the fact that there is most likely far
more HA present on the virions than there are molecules of CD9,
CD81 or CD59.
Discussion
Our proteomic analysis of influenza A virions has confirmed the
presence of nine virus-encoded proteins in the virus particle and for
the first time demonstrated the incorporation of cellular proteins. In
total 36 host proteins were identified with a confidence level .95%
based on matches of the peptide sequences with proteins in the
NCBI database, and 17 of these were detected using two
independent techniques. It is remarkable that of these 36 proteins,
25 have also been described to be present in virions of quite diverse
virus families (e.g. herpesviruses, poxviruses, retroviruses–see
Tables 2–4). Considering that these studies were performed
independently using different cell types and different mass
spectrometry methods, this similarity is probably not an issue of
contamination. The most likely explanation is that these viruses all
share some fundamental feature and that these host proteins are
involved in the processes associated with that common trait. For
instance it could simply be that they are all enveloped viruses.
Enveloped viruses must all enter the cell via a membrane fusion
event and exit by budding, be it from the plasma membrane or an
internal membrane. Therefore one hypothesis would be that the
incorporated host proteins common to all these enveloped viruses
play a role in these particular stages of the virus life-cycle. Future
experiments involving RNAi knockdown of these host proteins and
also information on host factors associated with non-enveloped
viruses will help to address this question. The process of budding
Figure 4. Gradient fractionation demonstrates co-purification of influenza virus and CD9. Influenza A/WSN/33 virus was purified over (A)
sucrose and (B) Optiprep gradients. Fractions were taken from the top and analyzed by western blot for the presence of NP, CD9 and MHC-I, as
indicated. Numbers to the right are molecular weight markers.
doi:10.1371/journal.ppat.1000085.g004
Figure 3. The effect of protease treatment on influenza virion
associated host proteins. Purified influenza A/WSN/33 virus was
either mock treated or subjected to overnight digestion with subtilisin
followed by concentration through a sucrose cushion. 10 ug of mock
infected cell lysate (lane 1) or influenza infected cell lysate (lane 2) and
2 ug of untreated influenza virions (lane 3) or protease treated influenza
virions (lane 4) were then analyzed by western blot with antibodies
against the indicated proteins. Numbers to the right are molecular
weight markers.
doi:10.1371/journal.ppat.1000085.g003
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fortuitously at the budding site as the particle forms. Most likely,
these would be highly abundant cytosolic proteins, and several of
the proteins found within both influenza virus and other virus
particles would fall into this category (e.g. beta actin, enolase,
tubulin, GAPDH, pyruvate kinase). These proteins may be
examples of non-specifically incorporated proteins. Other, less
abundant, proteins may be incorporated because they are enriched
atthevirusbudding site.Someviruses,includinginfluenzavirusand
HIV-1 have been proposed to assemble at and bud from specific
microdomains in the plasma membrane termed ‘‘lipid rafts’’ [35–
39]. Lipid rafts are characterized as being rich in sphingolipids,
cholesterol and specific raft proteins, and lipid analysis of purified
HIV-1 virions has shown a composition strikingly similar to that of
lipid rafts [40]. Therefore it would not be unexpected to find lipid
raft-resident proteins within virus particles that bud from these
domains. Proteomic analysis of rafts derived from a number of
different cell types, including Vero cells, has been performed and
comparison of these proteins with those that were found to be
associated with influenza virions reveals some overlap [41–45].
These include tubulin, actin, annexins, enolase, GAPDH, glypican
4, gamma-glutamyltransferase, HSP 27 and transgelin. As a GPI-
anchored protein, CD59 is also considered to be a lipid raft protein.
It should be noted that some typical raft proteins such as caveolin
and flotillin were not identified in influenza virus particles and the
same is true for HIV-1 [11,40]. It is thought that this is because the
viral budding site is formed by the clustering of only a subset of rafts
which may be determined by the accumulation of specific viral
proteins [40]. The question remains as to whether the incorporation
of these raft proteins is secondary to the choice of budding site or
whether the budding site is selected due to the localized
concentration of these proteins.
Some cellular proteins may be specifically recruited and
packaged into the virion, presumably via an interaction with
either a viral protein or even the viral genome. There is a high
probability that such proteins are actively involved in the virus life
cycle, either at late stages during virus assembly and egress from
the producer cell or at early stages of entry into the new target cell.
A number of the proteins identified in influenza virions have been
reported to play a role during certain stages of the infection
process for a variety of viruses and this may provide a clue as to
why they are present in the influenza virion. These include:
i) Cytoskeletal proteins
The host cytoskeletal network is involved in the transport of
viral components in the cell and particularly during the stages of
virus entry and exit [46,47]. Several studies on RNA viruses have
also indicated that cytoskeletal proteins such as tubulin and actin
are required for viral gene expression [48–51]. For influenza virus,
it has been shown that the virus requires an intact actin
cytoskeleton for entry, specifically into polarized cells [52] and
interactions between the cytoskeleton and lipid rafts has been
proposed to facilitate budding of filamentous virus particles [53].
Furthermore, an association of M1 and NP with cytoskeletal
elements has been reported [54,55], and actin and tubulin were
both identified as proteins that interact with influenza RNPs [21].
In the present study, protease treatment showed that actin, tubulin
and cofilin (which binds to actin) were all present in the interior of
influenza virions which most likely reflects their active participa-
tion in moving the viral components to the assembly site as well as
cytoskeletal reorganization that occurs during bud formation.
Other actin-binding proteins found to be associated with influenza
virions are tropomyosin, annexin (see below), WD repeat
containing protein and destrin.
ii) Annexins
Several annexin family members (A1, A2, A4, A5 and A11)
were identified in influenza virus particles. Annexins are calcium-
dependent phospholipid-binding proteins and are proposed to act
as scaffolding proteins at certain membrane domains. Annexin A2
in particular has been shown to bind to actin and be involved in
the assembly of actin at cellular membranes [56]. It is also
required for the apical transport of vesicles in polarized cells and
specifically vesicles that carry membrane raft-associated proteins
[57]. This is intriguing since influenza virus also buds from raft
domains at the apical surface of polarized cells. In fact, a role for
annexin A2 in virus assembly has been proposed for HIV-1 [58],
and in HCMV, the presence of annexin A2 is thought to promote
viral binding and fusion [59]. Interestingly, annexins A1 and A5,
which both interact with A2, have the opposite effect of preventing
fusion, perhaps indicating a potential regulatory role [60]. The
calcium-binding protein S100A11 which is known to interact with
annexin A1 [61] was also identified in the influenza virion,
suggesting that they may be packaged as a complex.
iii) Tetraspanins
Two members of the tetraspanin family, CD9 and CD81, were
found to be associated with influenza virions and are most likely
inserted into the viral envelope. Tetraspanins have four transmem-
brane domains and two extracellular loops and are involved in both
homo- and heterotypic interactions in specialized membrane
domains referred to as tetraspanin-enriched microdomains (TEMs)
[62]. Despite some similarities to lipid rafts, proteomic analyses of
TEMs and lipid rafts have shown that they have distinct
compositions [63], although they may interact with each other
under certain conditions. Several tetraspanins have been reported to
Figure 5. Immunogold labeling of host proteins in purified
influenza virions. Influenza virions purified from the supernatant of
infected Vero cells were immunogold labeled with antibodies against
(A) Hemagglutinin, (B) CD9, (C) CD81 and (D) normal mouse IgG.
Labeled virus was negatively stained with sodium silicotungstate and
visualized by electron microscopy (50,0006magnification). The number
of gold particles per virion is shown below (n=the number of virions
counted).
doi:10.1371/journal.ppat.1000085.g005
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characterized in terms of its function as a co-receptor for hepatitis C
virus [64,65]. Tetraspanins, including CD9 and CD81, have also
been implicated in both fusion and egress pathways for a number of
viruses such as HIV-1, feline immunodeficiency virus and canine
distemper virus [66–70]. One such study also reported that in
contrasttoHIV,influenzavirusdoesnot assemble at domains richin
tetraspanins and does not incorporate either CD9 or CD63 into
virus particles [71]. This finding is obviously contradictory to the
present proteomic analysis of influenza virions in which CD9 was
detected by mass spectrometry, immunoblot analysis and immuno-
gold labeling of virions. The reason for the discrepancy may be
technical as Khurana et al. [71] used HeLa cells to propagate the
virus and detected incorporated proteins by immunofluorescent
staining ofconcentratedvirions.Integrinbeta-1wasalso identifiedin
influenza virus particles and as integrins are well-characterized
tetraspanin binding partners, it was possibly incorporated together
with CD9 or CD81.
iv) Cyclophilin A
Cyclophilin A (CypA), which was shown to be in the core of
the influenza virion, is a peptidyl-prolyl isomerase and has been
reported to be present in the virions of a number of different
viruses. For HIV-1, the specific incorporation of CypA is
mediated by an interaction with the capsid portion of the Gag
protein [15,16]. There is an abundant amount of literature
concerning the requirement of CypA for HIV-1 infectivity but as
it turns out, it is the CypA in the target cell that is more critical
and therefore the precise role of the virion CypA is currently
unclear [72,73]. Within the target cell, CypA is proposed to
facilitate a conformational change in the capsid which enables
the virus to evade detection by the host immune response
[74,75]. CypA is incorporated into vesicular stomatitis virus
(VSV) presumably via the described interaction with the
nucleocapsid protein [76]. It has also been shown to be required
for VSV replication, however this activity is serotype-specific
[76]. A strong interaction between CypA and SARS coronavirus
nucleocapsid protein has also been reported [77] and CypA
relocalizes to sites of viral replication in vaccinia virus infected
cells [78]. Another member of the cyclophilin family, cyclophilin
B, is required for hepatitis C virus replication and acts by
interacting with the viral polymerase and increasing its RNA
binding activity [79]. Therefore, there is a strong precedent for
the involvement of cyclophilin proteins in virus replication.
v) CD59
CD59 is a complement regulatory protein that acts by inhibiting
formation of the membrane attack complex (MAC). It is a GPI-
anchored protein and the experimental data confirm that it is
associated with the influenza virus envelope. Enveloped viruses are
susceptible to direct complement-mediated lysis by MAC and as a
form of protection HIV-1, vaccinia virus (VV), human T cell
lymphotropic virus (HTLV) and human cytomegalovirus (HCMV)
all incorporate CD59 and other regulatory proteins such as DAF
and CD46 into their lipid envelopes (the latter two were not
identified in influenza virions) [80–82]. Complement control
proteins are highly species specific and are only active against
homologous complement. This has important implications for
virus host-range as the virus produced and transmitted between
one host species would be protected by incorporation of CD59/
DAF/CD46, however, virus transmitted to another host species
would become susceptible to lysis by the complement system of
that host.
vi) Glycolytic enzymes
When one looks at the list of proteins associated with influenza
virions, at first glance it is difficult to see an obvious role for some
of these proteins in the virus life cycle. However, it is possible that
some of these cellular proteins have functions other than their
described major roles. For example, a number of proteins involved
in the glycolytic pathway were identified (pyruvate kinase, enolase
1, GAPDH, phosphoglycerate kinase). Both enolase and phos-
phoglycerate kinase, in addition to tubulin, have been reported to
stimulate transcription of the Sendai virus genome [83], but it is
unclear whether their glycolytic activities are required or whether
this is an example of an alternative function for these proteins [84].
A role in RNA virus transcription has also been proposed for
GAPDH. Phosphorylated forms of GAPDH have been shown to
bind to the genomic cis-acting RNA of human parainfluenza virus
type 3 (hPIV3) and are also present in purified virions [85,86]. In
vitro data indicate that GAPDH serves a negative regulatory role in
hPIV3 transcription and that this is dependent on its phosphor-
ylation [85].
Compared with the cellular proteins found to associate with the
influenza RNP complex, the only ones also identified in influenza
virions are alpha and beta tubulins, beta actin and ubiquitin
carboxyl-terminal hydrolase [21]. This may indicate that these
proteins are packaged with RNPs and that they interact with one
of the RNP components i.e. NP, one of the polymerase proteins or
the genomic RNA. The fact that there are not more proteins in
common is probably because each viral protein associates with
many different cellular proteins during the course of the viral life
cycle and these interactions in most cases are transient. The
proteins identified in this and other studies represent a snapshot of
a particular point in the life cycle, but importantly they provide a
foundation for further analysis of cellular requirements for
influenza virus infection. Packaged cellular proteins have a unique
importance as the virus literally transports them from one cell to
the next. This is an ingenious way of ensuring that host cell
activities required at or immediately after entry are instantly
accessible to the virus. For viruses that can infect multiple species
such as influenza virus, any host protein that is required for
infection must be active in both species to allow for transmission to
occur. Therefore, as discussed above for CD59, virion-associated
host proteins can be one of the determinants of virus host range
due to their species-specific activity. It will also be interesting to
compare the identity and abundance of host proteins in influenza
viruses that produce virions with a filamentous morphology. One
would assume that the increased volume and surface area of these
particles would allow for greater levels of host protein incorpora-
tion but whether or not there is increased diversity may depend on
specific versus non-specific incorporation.
The presence of host proteins in influenza virions, whether
they are incorporated specifically or non-specifically, could also
be a concern for vaccine manufacturers as the vaccine is
delivering more than just viral antigens. Although the relative
amount of cellular protein compared to viral protein in the virus
particle is expected to be extremely small, the choice of host cell
for propagation of vaccines could be an important consideration,
particularly for live-attenuated virus vaccines. Currently, all
influenza vaccines are produced in embryonated chicken eggs
but there is a move afoot to transition to cell culture systems,
with Vero cells being one of the approved cell lines [87,88].
During the manufacturing process great care is taken to avoid
the use of animal-derived products such as serum but the
incorporation of non-human primate proteins into the vaccine
virus will be unavoidable. Precise quantitation of these non-viral
components will help to assess whether the levels present in each
Host Proteins in Influenza Virions
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response.
Materials and Methods
Cells, virus and antibodies
Vero and A549 cells were maintained in Dulbecco’s modified
Eagle medium (Gibco, San Diego, California) supplemented with
10% fetal bovine serum (HyClone, South Logan, Utah) and
Madin-Darby canine kidney (MDCK) cells were maintained in
minimal essential medium supplemented with 10% fetal bovine
serum. Influenza A/WSN/33 virus was propagated in MDCK
cells in Minimal Essential Medium (Gibco) supplemented with
0.3% bovine serum albumin (Sigma, St. Louis, Missouri) and 0.1%
fetal bovine serum. Viral titers were determined by plaque assay
on MDCK cells.
Antibodies against actin (A4700), annexin A5 (A8604), cofilin
(C8736) and tubulin (T0198) were obtained from Sigma (St.
Louis, Missouri). Monoclonal antibody against annexin A2 (sc-
28385) was obtained from Santa Cruz Biotechnology (Santa
Cruz, California). Monoclonal antibodies against CD9 (sc-13118
and 555370) were obtained from Santa Cruz Biotechnology and
BD Pharmingen (San Diego, California), respectively. Monoclo-
nal antibody against CD59 (MCA1054GA) was obtained from
Serotec (Oxford, U.K.) and monoclonal antibody against CD81
(555675) was obtained from BD Pharmingen. Rabbit polyclonal
antibody against cyclophilin A (SA-296) was obtained from
Biomol (Plymouth Meeting, Pennsylvania) and monoclonal
antibody against GAPDH (RDI-TRK5G4-6C5) was obtained
from RDI Research Diagnostics (Concord, Massachusetts).
Monoclonal antibodies against influenza virus NP (HT103) and
HA (2G9) were made by the Mount Sinai Hybridoma Center
Shared Research Facility. The MHC-I antibody was kindly
provided by Dr. Domenico Tortorella (Mount Sinai School of
Medicine, NY).
Purification of influenza virus
Fifty 15cm dishes of 80% confluent Vero cells were infected
with influenza A/WSN/33 virus at a multiplicity of 0.001. At
65–70 hours post infection, the supernatant was harvested and
clarified (26006g,5m i n ,4 uC, in a Sorvall RT6000D centrifuge).
The clarified supernatant was layered over a 20% sucrose
cushion in NTE buffer (100 mM NaCl, 10 mM Tris-Cl (pH 7.4),
1 mM EDTA) and the virus concentrated by ultracentrifugation
(112,6006g, 2 hrs, 4uC, in a SW28 rotor [Beckman Coulter,
Fullerton, California]). The concentrated virus was purified over
a 30–60% sucrose gradient (112,6006g,3 h r s ,4 uC) and the
banded virus collected, diluted with NTE buffer, pelleted
(112,6006g,9 0m i n ,4 uC) and resuspended in approximately
1 ml of NTE buffer. Typical protein yields of 1–2 mg/ml were
obtained. When using Optiprep medium (Sigma, St. Louis,
Missouri), a 10–30% gradient was made and fractions were
taken from the top. Protein was precipitated from each fraction
with 20% trichloroacetic acid (TCA) and subjected to western
blot analysis.
Deglycosylation of virion proteins
Purified virus equivalent to 100 ug of protein was denatured by
heating at 100uC for 10 min in the presence of 0.5% SDS, 40 mM
DTT and 1%NP40. PNGase F (New England Biolabs, Ipswich,
Massachusetts) was added in the presence of 50 mM sodium
phosphate (pH 7.5) and 1% NP40 and the reaction incubated at
37uC overnight.
Protease treatment of virions
Purified virus equivalent to 50 ug of protein was incubated with
100ug of subtilisin protease (Sigma, St. Louis, Missouri) in 20 mM
Tris-Cl (pH 8) and 1 mM CaCl2 for 18 hours at 37uC. The
treated virus was diluted to 1 ml with NTE buffer and 5ug of
PMSF (Sigma) was added. The virus was concentrated through a
20% sucrose cushion by ultracentrifugation (222,0306g, 2 hr, 4uC
in an SW41 rotor [Beckman Coulter, Fullerton, California]) and
then subjected to western blot analysis.
Protein gel electrophoresis and Immunoblot analysis
Vero or A549 cells at 80% confluency were mock infected or
infected with influenza A/WSN/33 virus at a multiplicity of 0.001.
At 65–70 hours post infection the cells were harvested and whole
cell extracts were prepared by lysis in extract buffer (50 mM Tris
[pH 7.5], 280 mM NaCl, 1% Triton X-100, 0.2 mM EDTA,
2 mM EGTA, 10% glycerol, 1 mM dithiothreitol, 0.1 mM
sodium vanadate and protease inhibitors [Complete; Roche]) on
ice for 30 minutes. Extracts were centrifuged (157006g, 15 min,
4uC in an Eppendorf 5415R microcentrifuge) and the superna-
tants collected. Proteins from either purified virus (2 ug) or whole
cell extracts (10 ug) were denatured by heating at 100uC for
10 min in 16sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer and were then separated by
SDS-PAGE. For western blot analysis the proteins were
transferred to nitrocellulose membrane which was then probed
with a specific primary antibody and a peroxidase-labeled
secondary antibody. The blots were analyzed by chemilumines-
cence and exposed to x-ray film. For protein staining, gels were
stained with SimplyBlue SafeStain (Invitrogen, Carlsbad, Califor-
nia).
Electron microscopy and Immunogold labeling
Optiprep-purified virus was diluted 1:20 with NTE buffer and
adsorbed onto formvar/carbon-coated nickel grids (Electron
Microscopy Sciences, Hatfield, Pennsylvania). Following a 5 min
wash with TBS buffer (50 mM Tris-Cl (pH 7.5), 150 mM NaCl),
the sample was blocked with 3%BSA in TBS for 45 min. Primary
antibody (10 ug/ml) was diluted in 1%BSA/TBS and adsorbed to
the grid for 1 hr at room temperature. Following three washes with
TBS, secondary gold-conjugated antibody was added for 1 hr at
room temperature. The grids were then washed twice with TBS,
once with water and negatively stained with 1% sodium
silicotungstate (pH 7) for 15 sec. Images of stained virions were
captured on a Hitachi H-7650 120 kV transmission electron
microscope. For quantitation purposes, the number of virions and
the number of gold particles were assessed in two representative
images. These data were expressed as the number of gold particles
per virion.
Protein identification from gel slices
Proteins separated in one dimensional polyacrylamide gels were
cut sequentially and subjected to in situ tryptic digestion prior to
mass spectrometric analysis. Digestion was performed robotically
on the GE Healthcare Ettan Gel Digester in a 96 well plate. A
20 minute wash with 100 ml, 50 mM ammonium bicarbonate in
50% acetonitrile was followed with a 10 minute 75% acetonitrile
wash. Gel bands were then air dried and 15 ml of 6.7 mg/ml
sequencing grade trypsin (Promega) was added to each well.
Digestion was carried out at 37uC for 16 hours. The protein
digests were then analyzed using Waters/Micromass QTOF
Ultima mass spectrometer equipped with a Waters CapLC liquid
chromatography system. 10 ml of the digest supernatant was
Host Proteins in Influenza Virions
PLoS Pathogens | www.plospathogens.org 10 June 2008 | Volume 4 | Issue 6 | e1000085loaded into a capLC vial and 5 ml of the sample was directly
injected onto a 100 mm i.d.6150 mm long Atlantis C18 reversed
phase column (Waters) running at 500 nl/min. Initial HPLC
conditions were 95% buffer A and 5% buffer B with the following
linear gradient: 3 min, 5% B; 43 min 37% B; 75 min 75% B; and
85 min 95% B. Buffer A consisted of 98% water, 2% acetonitrile,
0.1% acetic acid, and 0.01% TFA. Buffer B contained 80%
acetonitrile, 20% water, 0.09% acetic acid, and 0.01% TFA.
Data-dependent acquisition was performed so that the mass
spectrometer switched automatically from MS to MS/MS modes
when the total ion current increased above the 1.5 counts/second
threshold set point. In order to obtain good fragmentation, a
collision energy ramp was set for the different mass sizes and
charge states, giving preference to double- and triple-charged
species for fragmentation.
All raw MS/MS spectral data were searched in-house using
the MASCOT algorithm (Matrixscience) with the Mascot
Distiller program utilized to generate Mascot compatible files.
The Mascot Distiller program combines and centroids sequential
MS/MS scans from profile data that have the same precursor
ion. A charge state of +2a n d+3 was preferentially located with a
signal to noise ratio of 1.2 or greater and a peak list was
generated for database searching. Using the Mascot database
search algorithm, a protein was considered identified when
Mascot listed it as a significant match/score (p,0.05) with the
proper enzymatic cleavage sites. Unlike the MudPIT analysis
(see below), the Peptide/Protein Prophet (Institute for Systems
Biology) scoring system was not used here because this would
have required either combining the data from all gel slices or
treating each gel slice as an individual Peptide/Protein Prophet
model. Combining the gel slices may allow for an effective
PeptideProphet expectation maximization model to be built but
would create false protein identifications in that a protein
probability could be based on peptides present in separate bands
on the gel. Applying Peptide/Protein Prophet to individual gel
slices would result in a collection of small datasets (50–100 MS/
MS queries) that cannot be modeled accurately as there are not
sufficient datapoints for the expectation maximization algorithm
to assign correct versus incorrect peptides.
The NCBInr protein database was chosen over other genome
specific databases to allow a wider search match found based on
homology to other species. Parameters used for searching were
partial methionine oxidation and acrylamide modified cysteine, a
peptide tolerance of 60.6 Da, and a MS/MS fragment tolerance
of 60.4 Da.
MudPIT protein identification
100 mg of deglycosylated purified virus preparation was
solubilized in 8 M Urea, 0.4 M NH4HCO3 (pH 8.0), reduced
with 45 mM DTT, and alkylated with 100 mM iodoacetamide.
Tryptic digestion was performed using a 1:50 enzyme to substrate
ratio at 37 degrees C for 18–24 hours (sequencing grade trypsin,
Promega). After digestion, off-line strong cation exchange
chromatography (SCX) was performed on an Applied Biosystems
Vision Workstation using a 2.1 mm6200 mm PolySulfoethyl A
column, equilibrated with Buffer A (10 mM KH2PO4, 25%
Acetonitrile, pH=3.0). Peptides were separated into fractions
using a 90 min linear salt gradient from 0–98% Buffer B (10 mM
KH2PO4, 25% Acetonitrile, 1 M KCl, pH=3.0) All 22 collected
fractions from the SCX chromatography were dried and
reconstituted with 15 ml of 0.1 % TFA. A 5 ml aliquot of each
of the samples was injected and desalted on a reversed phase C18
trap column (Waters, Symmetry, Nanoease 0.180 mm
i.d.623.5 mm, 5 micron) and was separated on a C18 analytical
column (Waters, Atlantis, Nanoease 0.1 mm i.d.6150 mm,
3 micron, 100 A ˚) using the Dionex Ultimate chromatography
system. On-line MS analysis was performed on the ABI QSTAR
XL system. MS data was surveyed for 0.5 s, and MS/MS
acquisition was performed on three highest peptide peaks.
Each of the QSTAR XL mass spectrometer spectra files was
processedwithMASCOTDistillerversion2.1andtheresultingpeak
lists were databasesearched using MASCOT Server 2.1. The search
parameters included static carbamidomethyl modifications for
cysteine and variable oxidation modifications for methionine amino
acid residues. Data analysis on the resulting LC/MS and MS/MS
datasets is accomplished using a dual processor Dell 650
Workstation. The search results for each fraction were analyzed
using the NCBInr database. After MASCOT analysis, Peptide and
ProteinProphet (Institute for Systems Biology) analysis was per-
formed using the Trans-Proteomic Pipeline version 2.9 GALE rev.1,
Build 200607201423. Peptide and Protein Prophet computes the
probabilitiesforbothindividuallysearchedpeptidesandtheresulting
proteins. The 95% Protein Prophet probability cutoff corresponds to
a 0.6% false positive error rate. Finally, TPP identifications are
submitted to Yale Proteomics Expression Database (YPED) web site
[89] for further user analysis. All data are publicly available through
http://yped.med.yale.edu/repository.
Supporting Information
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